Stay updated with breaking news from Nasdaq Srpt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $166.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 26.81% […]
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Stock analysts at William Blair reduced their FY2024 EPS estimates for Sarepta Therapeutics in a research report issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $6.66 for the year, down from their previous […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price […]